SOD1 and amyotrophic lateral sclerosis: As regards current clinical scenarios, tcMRgFUS sonopermeation has recently been used to induce a transitory BBB permeation localized at the primary motor cortex of some ALS volunteers, without clinically and electrophysiologically noticeable complications, opening up the possibility of targeted therapy such as localized delivery of superoxide dismutase (SOD) inhibitors [76].